Home Rehabilitation for Pulmonary Hypertension
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it requires that you have been on stable vasodilator dosing for at least 30 days before starting the study, with no planned changes during the 12-week study period.
What data supports the effectiveness of the treatment Home Rehabilitation for Pulmonary Hypertension?
Research shows that home-based rehabilitation programs can be effective and safe for patients with pulmonary arterial hypertension, improving their exercise capacity and quality of life. Similar programs have also been beneficial for other heart and lung conditions, suggesting that home rehabilitation can be a valuable part of managing pulmonary hypertension.12345
Is home rehabilitation safe for people with pulmonary hypertension?
How is home rehabilitation different from other treatments for pulmonary hypertension?
Home rehabilitation for pulmonary hypertension is unique because it allows patients to perform supervised exercise programs at home, making it more accessible and convenient compared to traditional hospital-based programs. This approach can improve exercise capacity and is designed to be safe and effective for patients with stable pulmonary arterial hypertension.134910
What is the purpose of this trial?
The purpose of this study is to evaluate whether a home rehabilitation program for patients diagnosed with Pulmonary Arterial Hypertension (PAH) will decrease Cardiac Effort (number of heart beats used during 6-minute walk test/walk distance) and improve quality of life. Ultimately, this information could help improve the management of patients with PAH.
Eligibility Criteria
This trial is for patients with Pulmonary Arterial Hypertension (PAH), a type of high blood pressure affecting the lungs. Participants should be able to perform physical activities as part of a home rehabilitation program aimed at reducing cardiac effort and improving quality of life.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo a home rehabilitation program aimed at decreasing cardiac effort and improving quality of life
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Home Rehabilitation
Home Rehabilitation is already approved in European Union, United States for the following indications:
- Pulmonary Arterial Hypertension (PAH)
- Improvement of Cardiac Effort
- Enhancement of Quality of Life
- Pulmonary Arterial Hypertension (PAH)
- Improvement of Cardiac Effort
- Enhancement of Quality of Life
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Rochester
Lead Sponsor
United Therapeutics
Industry Sponsor
Dr. Martine Rothblatt
United Therapeutics
Chief Executive Officer since 1996
PhD in Medical Ethics from the Royal London College of Medicine and Dentistry, JD and MBA from UCLA
Dr. Michael Benkowitz
United Therapeutics
Chief Medical Officer since 2023
MD from Harvard Medical School
Mayo Clinic
Collaborator